ArticleFrontiers in pharmacology2022
Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Comprehensive Characterization of Antidepressant Pharmacogenetics: A Systematic Review of Studies in Major Depressive Disorder.Clinical and translational science · 2025Pooled it
- Bridging Ancestry-Stratified Bias in Pharmacogenomics AI: Toward Metabolomics-Inclusive Multi-Omics Precision Medicine.Journal of personalized medicine · 2026Review
- Amino Acid-Fatty Acid Profile as a Novel Predictive Method in the Assessment of Diagnosis and Treatment Efficacy of Anxiety-Related Disorders and Mood Disorders.International journal of molecular sciences · 2026Review
- Pharmaco-multiomics in major depressive disorder: a narrative review and proposed translational framework for difficult-to-treat and treatment-resistant depression.Frontiers in pharmacology · 2026Review
- Artificial intelligence, medications, pharmacogenomics, and ethics.Pharmacogenomics · 2024Article
- Multi-omics in stress and health research: study designs that will drive the field forward.Stress (Amsterdam, Netherlands) · 2024Review
- Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research.Molecules (Basel, Switzerland) · 2023Review
- Potential links between brown adipose tissue, circadian dysregulation, and suicide risk.Frontiers in neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.